Financial Data and Key Metrics Changes - Consolidated adjusted net income reached PEN 136 million in Q4 2025, compared to PEN 36 million in the same quarter last year, with full-year adjusted net income more than tripling to PEN 336 million [9][22] - Consolidated revenue grew 6% at FX neutral in Q4, while adjusted EBITDA declined 14% FX neutral, reflecting Mexico's underperformance and an unfavorable year-over-year comparison in Colombia [10][19] - For the full year, revenue grew 4%, while EBITDA declined 3% [10][21] - Free cash flow grew 35% to PEN 582 million, and year-end cash position increased 42% to PEN 335 million [27][29] Business Line Data and Key Metrics Changes - Mexico's revenues declined 3% in Q4, but showed stabilization with unchanged revenues from the previous quarter [11][12] - Peru's revenue increased 11% during Q4, driven by growth in high complexity services and a record low medical loss ratio [16] - Colombia's revenue increased 6% for the quarter, with a full-year revenue increase of 4%, mainly driven by higher ticket prices [18] Market Data and Key Metrics Changes - Capacity utilization in healthcare services decreased 2.3 percentage points to 64%, particularly in Colombia [10] - In Mexico, out-of-pocket revenues increased to 12% of total revenues in December, reflecting early recovery stages [11] - The oncology medical loss ratio in Peru improved to a record low of 48.5% [16] Company Strategy and Development Direction - The company aims to recover growth levels in Mexico and expand its reach into larger segments of privately insured families [6][31] - Auna is focusing on diversifying away from intervened payers in Colombia and prioritizing cash flows through risk-sharing arrangements [31] - The company plans to continue investing in strategic growth initiatives, particularly in Mexico and Peru, with expected adjusted EBITDA growth of 12% FX neutral in 2026 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the business and the outlook for 2026, citing improvements in Mexico's operations and strong performance in Peru [40][41] - The main risks to guidance include the pace of volume recovery in Mexico and macroeconomic conditions in operating markets [40] - Management highlighted the importance of maintaining a higher mix of services and specialties to improve margins in Mexico [84] Other Important Information - The company successfully refinanced $825 million in debt, improving its maturity profile and lowering interest expenses [9][29] - The extension of the healthcare plan with ISSSTE León is expected to result in a double-digit price increase for 2026 [49] - The Torre Trecca project is expected to commence operations in the second semester of 2028, representing a significant opportunity for Auna [52] Q&A Session Summary Question: Can you break down guidance by region or business line? - Management indicated that Mexico is expected to drive most of the improvement, but they are not providing guidance by country at this time [35][43] Question: What are the risks to your 2026 guidance? - Management noted that external factors such as political headwinds and operational challenges in Mexico were previously concerns, but they are now confident in the stability of the business [40] Question: Can you provide updates on the Torre Trecca project? - Management confirmed that Torre Trecca will commence operations in the second semester of 2028 and is expected to represent about 25% of the business in Peru at maturity [52] Question: What is the expected CapEx for 2026 and beyond? - Management stated that CapEx for 2026 is expected to be approximately 4% of revenue, focusing on maintenance investments and technology [61] Question: How is the board prioritizing capital allocation? - Management discussed the potential for share buybacks but emphasized that growth opportunities in Mexico would take priority [78]

Core Insights - The current open enrollment period is leading to significant changes in health care plans, with millions expected to see sharp increases in insurance premiums next year [1][2] - The health care system is facing ongoing issues, including rising costs and confusion surrounding subsidies, particularly in relation to the Affordable Care Act (ACA) [3][4] Health Insurance Industry Overview - Approximately 50% of American small businesses utilize the ACA, which is crucial as small businesses represent 50% of the GDP [4] - Farmers, who average a gross income of $60,000, are particularly affected, with premiums expected to rise from $75 to $300 due to the end of enhanced subsidies [4][5] - Currently, 100 million Americans lack access to employer-sponsored health insurance, highlighting a significant gap in coverage [6] Economic Impact - The ACA has reduced the uninsured rate from 15% to 8%, saving $10 billion annually in uncompensated care costs [7] - If the uninsured rate increases again, it could lead to an $80 billion problem over the next decade [8] Proposed Solutions - A suggestion to create a qualified account system is presented, allowing consumers to manage their healthcare spending, which could help control costs [10][11] - The idea of Health Savings Accounts (HSAs) is discussed as a way to empower consumers to make informed choices about their healthcare [15][17] - The need for technology and support to help individuals select appropriate plans and manage out-of-pocket costs is emphasized [12] Political Landscape - There is a call for evolving the ACA rather than completely replacing it, with a focus on providing subsidies where needed [17][19] - The discussion includes the potential for competition to drive down costs, but concerns remain about where the margins will be affected within the healthcare system [21][22]

Core Insights - Molina Healthcare experienced a significant stock decline of over 17% following its quarterly earnings report, contrasting with a positive market trend where the S&P 500 gained 0.6% [1] Financial Performance - In Q3, Molina's total revenue reached nearly $11.5 billion, marking an 11% year-over-year increase, but net income fell sharply to $97 million ($1.84 per share) from $347 million in the previous year [2][3] - The company surpassed the average analyst revenue estimate of $10.94 billion but significantly missed the consensus for adjusted net income, which was projected at $3.91 per share [3] Business Segments - CEO Joseph Zubretsky indicated that approximately half of the company's underperformance was attributed to the marketplace business, while Medicaid maintained strong margins despite some pressure [3] Future Guidance - Molina revised its 2025 guidance, slightly increasing the revenue forecast to $44.5 billion but lowering the adjusted net profit estimate to $742 million, or about $14 per share, which still falls short of analyst expectations of just under $45.6 billion and $18.62 per share [4][6]

Core Viewpoint - Molina Healthcare's stock plummeted over 20% following a significant earnings miss for Q3, attributed to rising medical expenses and a lowered guidance for Q4 [1][2]. Financial Performance - Molina's adjusted EPS for Q3 was $1.84, missing analyst expectations of $3.89 by more than 50% [2]. - The company projects Q4 adjusted earnings of $0.35, significantly below analysts' expectations of $2.42 [2]. Medical Care Ratio (MCR) - Molina's consolidated MCR for Q3 was 92.6%, up from 89.2% in the same quarter last year, indicating increased medical expenses impacting profitability [4]. - A 92.6% MCR means the company retained only 7.4 cents per dollar of premium revenue after covering medical expenses [5]. - The MCR for ACA plans was particularly high at 95.6%, exceeding both analyst predictions of 86% and Molina's own 73% from the previous year [6]. Industry Context - The MCR is a critical metric for healthcare providers, reflecting the balance between premium revenue and medical expenses [3]. - Rising medical costs and the structure of ACA plans have posed significant challenges for Molina, affecting its financial stability [5][6].

Core Viewpoint - Centene experienced a significant drop in stock price, closing down over 40% on July 2, resulting in a loss of over $11 billion in market capitalization, with competitors also facing declines [1][2][5] Group 1: Financial Impact - The drop in Centene's shares was primarily due to the withdrawal of its 2025 full-year guidance, indicating a more challenging financial outlook [2][4] - The company received data indicating lower growth in the ACA exchange market and higher morbidity among enrollees, leading to fewer and sicker patients [3][4] - The expected impact on Centene's 2025 diluted earnings per share (EPS) is a reduction of $2.75, which is 38% of the previously expected EPS of greater than $7.25 [4][5] Group 2: Market Valuation - Despite the significant stock sell-off, Wall Street analysts see a more attractive valuation for Centene, with a 12-month price target of $68.87, implying a potential upside of 108.31% from the current price [5][6] - The average price target post-guidance withdrawal is $51, suggesting a 53% upside, which is higher than the 32% average upside prior to the drop [6][7] Group 3: Regulatory Environment - The recent legislation signed into law includes $1 trillion in cuts to Medicaid, which accounted for approximately 46% of Centene's revenue last quarter, potentially leading to 10.3 million to 11.8 million fewer Medicaid recipients over the next decade [8][9] - The reduction in expected Medicaid users could have a more significant and lasting impact on Centene compared to the ACA exchange enrollment issues, which only made up 20% of the firm's total revenue last quarter [9]